A BILL 
To direct the Secretary of Health and Human Services and 
other Federal officials to compile into a searchable data-
base information relating to Federal support for bio-
medical research and development related to COVID– 
19, and for other purposes. 
15:45 Mar 24, 2021
H1391
2 
•HR 1391 IH
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Taxpayer Research 
4
and Coronavirus Knowledge Act of 2021’’. 
5
SEC. 2. DATABASE. 
6
(a) IN GENERAL.—The Secretary of Health and 
7
Human Services, the Director of the National Institutes 
8
of Health, the Assistant Secretary for Preparedness and 
9
Response of the Department of Health and Human Serv-
10
ices, the Director of the Biomedical Advanced Research 
11
and Development Authority, the Secretary of Defense, the 
12
Secretary of Veterans Affairs, the Director of the National 
13
Institute of Allergy and Infectious Diseases, and such 
14
other Federal officials as the Secretary of Health and 
15
Human Services determines to be relevant, acting in co-
16
ordination, shall— 
17
(1) compile into a searchable database informa-
18
tion relating to Federal support (before or after the 
19
date of enactment of this Act) for biomedical re-
20
search and development related to COVID–19 (in-
21
cluding biomedical research and development relat-
22
ing to a product or therapy that was later modified 
23
or repurposed to be used for COVID–19); and 
24
15:45 Mar 24, 2021
H1391
3 
•HR 1391 IH
(2) make such database available on the public 
1
website of the Department of Health and Human 
2
Services. 
3
(b) COVERED INFORMATION.—The information relat-
4
ing to Federal support referred to in subsection (a)(1) in-
5
cludes all contracts, funding agreements, licensing ar-
6
rangements, other transactions, and other arrangements 
7
entered into by or on behalf of the Federal Government 
8
and tax benefits provided with respect to research and de-
9
velopment, and manufacturing, of a drug (including a bio-
10
logical product), cell or gene therapy, or medical device 
11
intended to be manufactured, used, designed, developed, 
12
modified, repurposed, licensed, or procured to diagnose, 
13
mitigate, prevent, treat, or cure COVID–19, including the 
14
following: 
15
(1) Licensing agreements pursuant to section 
16
207 or 209 of title 35, United States Code. 
17
(2) Cooperative research and development 
18
agreements and licensing agreements pursuant to 
19
section 3710a of title 15, United States Code. 
20
(3) Funding agreements, as defined under sec-
21
tion 201 of title 35, United States Code. 
22
(4) Transactions, contracts, grants, cooperative 
23
agreements, other agreements, and other arrange-
24
15:45 Mar 24, 2021
H1391
4 
•HR 1391 IH
ments entered into pursuant to the following stat-
1
utes: 
2
(A) The Public Health Service Act (42 
3
U.S.C. 201 et seq.), including sections 301, 
4
319L, 421, and 480 of such Act (42 U.S.C. 
5
241, 247d–7e, 285b–3, 287a). 
6
(B) Section 105 of the National Institutes 
7
of Health Reform Act of 2006 (42 U.S.C. 
8
284n). 
9
(C) Chapter 139 of title 10, United States 
10
Code (10 U.S.C. 2351 et seq.), including sec-
11
tions 2358, 2371, 2371a, 2371b, and 2373. 
12
(5) Grants, contracts, and other transactions 
13
pursuant to section 2371, 2371a, or 2371b of title 
14
10, United States Code. 
15
(6) Procurement contracts and other agree-
16
ments pursuant to section 2373 of title 10, United 
17
States Code. 
18
(c) INFORMATION REQUIRED.—Notwithstanding any 
19
other provision of law, the Federal officials referred to in 
20
subsection (a) shall include in the database under sub-
21
section (a), with regard to each contract, funding agree-
22
ment, licensing agreement, other transaction, other ar-
23
rangement, or tax benefit described in subsection (b), at 
24
least the following information: 
25
15:45 Mar 24, 2021
H1391
5 
•HR 1391 IH
(1) The agency, program, institute, or other 
1
Federal Government entity providing the Federal 
2
grant, cooperative agreement, or other support. 
3
(2) The amount and period of Federal financial 
4
support with an itemized breakdown. 
5
(3) Other Federal nonfinancial support, includ-
6
ing the use of Federal personnel, Federal facilities, 
7
and Federal equipment. 
8
(4) The grant number, if applicable. 
9
(5) Associated clinical trial data, upon trial 
10
completion. 
11
(6) Associated patents and patent applications, 
12
specifying— 
13
(A) any Federal ownership in such patents 
14
and patent applications; 
15
(B) the expiration date of such patents 
16
and filing dates of such patent applications; and 
17
(C) the numbers of such patents and pat-
18
ent applications. 
19
(7) Associated periods of marketing exclusivity 
20
under Federal law and the durations of such peri-
21
ods. 
22
(8) The corporation, nonprofit organization, 
23
academic institution, person, or other entity receiv-
24
ing the Federal support. 
25
15:45 Mar 24, 2021
H1391
6 
•HR 1391 IH
(9) Any products (including repurposed prod-
1
ucts) approved, authorized, or cleared for marketing, 
2
or for which marketing approval, authorization, or 
3
clearance is being sought, the development of which 
4
was aided by Federal support, including— 
5
(A) the names of such products; 
6
(B) the prices of such products; and 
7
(C) the current and anticipated manufac-
8
turing capacity to produce such products. 
9
(10) The full terms of the contract, funding 
10
agreement, licensing agreement, other transaction, 
11
or other arrangement described in subsection (b). 
12
(d) FORMAT OF INFORMATION.—The database under 
13
subsection (a) shall be— 
14
(1) searchable and filterable according to the 
15
categories of information described in subsection (c); 
16
and 
17
(2) presented in a user-friendly format. 
18
(e) TIMING.—The database under subsection (a) 
19
shall be— 
20
(1) made publicly available not later than 1 
21
month of the date of enactment of this Act; and 
22
(2) updated not less than every 2 weeks. 
23
(f) DISCLOSURE.— 
24
15:45 Mar 24, 2021
H1391
7 
•HR 1391 IH
(1) IN GENERAL.—Notwithstanding any other 
1
provision of law, to the extent necessary for an offi-
2
cial referred to in subsection (a) to carry out this 
3
section, such official may require entities receiving 
4
Federal support referred to in subsection (a)(1) to 
5
disclose to the official any information relating to 
6
such Federal support and required to be included in 
7
the database under subsection (a). 
8
(2) INTERMEDIARY
COOPERATION.—Any ar-
9
rangement entered into by the Federal Government 
10
with an entity providing for such entity to enter into 
11
contracts, licensing agreements, grants, other trans-
12
actions, or other arrangements with third parties on 
13
behalf of the Federal Government shall require such 
14
entity to disclose in a timely manner any informa-
15
tion necessary for the Federal Government to fulfill 
16
its duties under this Act. With respect to any such 
17
arrangement in place as of the date of enactment of 
18
this Act, an official referred to in subsection (a) may 
19
require the entity to disclose to the official any infor-
20
mation required to be included in the database 
21
under subsection (a). 
22
(3) PENALTY FOR NONDISCLOSURE.—If an en-
23
tity that is required to disclose information pursuant 
24
to paragraph (1) or (2) fails to disclose such infor-
25
15:45 Mar 24, 2021
H1391
8 
•HR 1391 IH
mation by the date that is two weeks after the date 
1
on which the official requests such information, or 
2
by such reasonable deadline as the official may 
3
specify, whichever is sooner, then such entity shall 
4
be liable to the United States for a civil penalty in 
5
an amount not to exceed $10,000 for each day on 
6
which such failure continues. 
7
Æ 
15:45 Mar 24, 2021
H1391
